Evidence map›Paper›PMID 39507620›Full record

ArticleFrontiers in genetics2024

Identification of novel 3D-genome altering and complex structural variants underlying retinitis pigmentosa type 17 through a multistep and high-throughput approach.

Suzanne E de Bruijn, Daan M Panneman, Nicole Weisschuh, Elizabeth L Cadena, Erica G M Boonen, Lara K Holtes, Galuh D N Astuti, Frans P M Cremers, Nico Leijsten, Jordi Corominas and 16 more

Abstract read
In one paragraph

Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Suzanne E de BruijnDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Daan M PannemanDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Nicole WeisschuhCenter for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
Elizabeth L CadenaHuman Genetics Center, School of Public Health, University of Texas Health Science Center, Houston, TX, United States.
Erica G M BoonenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Lara K HoltesDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Galuh D N AstutiDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Frans P M CremersDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Nico LeijstenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Jordi CorominasDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Christian GilissenDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
Anna SkowronskaWest Midlands Regional Genetics Laboratory, Birmingham Woman's and Children's NHS Foundation Trust, Birmingham, United Kingdom.
Jessica WoodleyWest Midlands Regional Genetics Laboratory, Birmingham Woman's and Children's NHS Foundation Trust, Birmingham, United Kingdom.
Andrew D BeggsInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, United Kingdom.
Vasileios ToulisUCL Institute of Ophthalmology, University College London, London, United Kingdom.
Di ChenUCL Institute of Ophthalmology, University College London, London, United Kingdom.
Michael E CheethamUCL Institute of Ophthalmology, University College London, London, United Kingdom.
Alison J HardcastleUCL Institute of Ophthalmology, University College London, London, United Kingdom.
Terri L McLarenCentre for Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia.
Tina M LameyDepartment of Medical Technology and Physics, Australian Inherited Retinal Disease Registry and DNA Bank, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Jennifer A ThompsonDepartment of Medical Technology and Physics, Australian Inherited Retinal Disease Registry and DNA Bank, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Fred K ChenCentre for Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia.
John N de RoachCentre for Ophthalmology and Visual Science, The University of Western Australia, Perth, WA, Australia.
Isabella R UrwinDepartment of Medical Technology and Physics, Australian Inherited Retinal Disease Registry and DNA Bank, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Lori S SullivanHuman Genetics Center, School of Public Health, University of Texas Health Science Center, Houston, TX, United States.
Susanne RoosingDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Introduction: Autosomal dominant retinitis pigmentosa type 17 (adRP, type RP17) is caused by complex structural variants (SVs) affecting a locus on chromosome 17 (chr17q22). The SVs disrupt the 3D regulatory landscape by altering the topologically associating domain (TAD) structure of the locus, creating novel TAD structures (neo-TADs) and ectopic enhancer-gene contacts. Currently, screening for RP17-associated SVs is not included in routine diagnostics given the complexity of the variants and a lack of cost-effective detection methods. The aim of this study was to accurately detect novel RP17-SVs by establishing a systematic and efficient workflow. Methods: Genetically unexplained probands diagnosed with adRP (n = 509) from an international cohort were screened using a smMIPs or genomic qPCR-based approach tailored for the RP17 locus. Suspected copy number changes were validated using high-density SNP-array genotyping, and SV breakpoint characterization was performed by mutation-specific breakpoint PCR, genome sequencing and, if required, optical genome mapping. Results: Using this workflow, potential RP17-SVs were detected in eight probands of which seven were confirmed. Two novel SVs were identified that are predicted to cause TAD rearrangement and retinal enhancer- Discussion: In summary, we describe a validated multi-step pipeline for reliable and efficient RP17-SV discovery and expand the range of disease-associated SVs. Based on these data, RP17-SVs can be considered a frequent cause of adRP which warrants the inclusion of RP17-screening as a standard diagnostic test for this disease.

Indexed as

gene diagnosticsgene regulationinherited retinal dystrophiesretinitis pigmentosastructural variants

Identifiers

PMID39507620
PMCPMC11537883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.